vs

Side-by-side financial comparison of Freshworks Inc. (FRSH) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $228.6M, roughly 1.4× Freshworks Inc.). Freshworks Inc. runs the higher net margin — -2.1% vs -18.2%, a 16.1% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 16.5%).

Freshworks Inc. is a cloud-based software-as-a-service company, founded in 2010 in Chennai, India. The company provides cloud-based tools for customer relationship management (CRM), IT service management (ITSM), and e-commerce marketing.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

FRSH vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.4× larger
MDGL
$321.1M
$228.6M
FRSH
Growing faster (revenue YoY)
MDGL
MDGL
+194.3% gap
MDGL
210.8%
16.5%
FRSH
Higher net margin
FRSH
FRSH
16.1% more per $
FRSH
-2.1%
-18.2%
MDGL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FRSH
FRSH
MDGL
MDGL
Revenue
$228.6M
$321.1M
Net Profit
$-4.8M
$-58.6M
Gross Margin
84.8%
Operating Margin
11.6%
-18.6%
Net Margin
-2.1%
-18.2%
Revenue YoY
16.5%
210.8%
Net Profit YoY
-268.9%
1.4%
EPS (diluted)
$-0.02
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRSH
FRSH
MDGL
MDGL
Q1 26
$228.6M
Q4 25
$222.7M
$321.1M
Q3 25
$215.1M
$287.3M
Q2 25
$204.7M
$212.8M
Q1 25
$196.3M
$137.3M
Q4 24
$194.6M
$103.3M
Q3 24
$186.6M
$62.2M
Q2 24
$174.1M
Net Profit
FRSH
FRSH
MDGL
MDGL
Q1 26
$-4.8M
Q4 25
$191.4M
$-58.6M
Q3 25
$-4.7M
$-114.2M
Q2 25
$-1.7M
$-42.3M
Q1 25
$-1.3M
$-73.2M
Q4 24
$-21.9M
$-59.4M
Q3 24
$-30.0M
$-107.0M
Q2 24
$-20.2M
Gross Margin
FRSH
FRSH
MDGL
MDGL
Q1 26
84.8%
Q4 25
85.6%
Q3 25
84.7%
Q2 25
84.8%
Q1 25
84.8%
96.7%
Q4 24
84.9%
Q3 24
84.0%
Q2 24
83.8%
Operating Margin
FRSH
FRSH
MDGL
MDGL
Q1 26
11.6%
Q4 25
17.8%
-18.6%
Q3 25
-3.5%
-39.7%
Q2 25
-4.2%
-22.2%
Q1 25
-5.3%
-57.8%
Q4 24
-12.2%
-64.8%
Q3 24
-20.8%
-187.1%
Q2 24
-25.1%
Net Margin
FRSH
FRSH
MDGL
MDGL
Q1 26
-2.1%
Q4 25
86.0%
-18.2%
Q3 25
-2.2%
-39.8%
Q2 25
-0.8%
-19.9%
Q1 25
-0.7%
-53.4%
Q4 24
-11.3%
-57.5%
Q3 24
-16.1%
-172.0%
Q2 24
-11.6%
EPS (diluted)
FRSH
FRSH
MDGL
MDGL
Q1 26
$-0.02
Q4 25
$0.66
$-2.55
Q3 25
$-0.02
$-5.08
Q2 25
$-0.01
$-1.90
Q1 25
$0.00
$-3.32
Q4 24
$-0.07
$-2.50
Q3 24
$-0.10
$-4.92
Q2 24
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRSH
FRSH
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$548.2M
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$1.0B
$602.7M
Total Assets
$1.6B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRSH
FRSH
MDGL
MDGL
Q1 26
$548.2M
Q4 25
$781.4M
$198.7M
Q3 25
$813.2M
$295.7M
Q2 25
$926.2M
$186.2M
Q1 25
$995.3M
$183.6M
Q4 24
$1.1B
$100.0M
Q3 24
$1.1B
$232.7M
Q2 24
$1.0B
Total Debt
FRSH
FRSH
MDGL
MDGL
Q1 26
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Stockholders' Equity
FRSH
FRSH
MDGL
MDGL
Q1 26
$1.0B
Q4 25
$1.0B
$602.7M
Q3 25
$851.5M
$625.7M
Q2 25
$984.6M
$696.0M
Q1 25
$1.1B
$710.6M
Q4 24
$1.1B
$754.4M
Q3 24
$1.1B
$777.2M
Q2 24
$1.1B
Total Assets
FRSH
FRSH
MDGL
MDGL
Q1 26
$1.6B
Q4 25
$1.6B
$1.3B
Q3 25
$1.4B
$1.4B
Q2 25
$1.5B
$1.0B
Q1 25
$1.5B
$996.6M
Q4 24
$1.6B
$1.0B
Q3 24
$1.6B
$1.1B
Q2 24
$1.5B
Debt / Equity
FRSH
FRSH
MDGL
MDGL
Q1 26
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRSH
FRSH
MDGL
MDGL
Operating Cash FlowLast quarter
$62.4M
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRSH
FRSH
MDGL
MDGL
Q1 26
$62.4M
Q4 25
$62.3M
$-133.5M
Q3 25
$63.5M
$79.8M
Q2 25
$58.6M
$-47.1M
Q1 25
$58.0M
$-88.9M
Q4 24
$41.4M
$-104.5M
Q3 24
$42.3M
$-67.0M
Q2 24
$36.3M
Free Cash Flow
FRSH
FRSH
MDGL
MDGL
Q1 26
Q4 25
$60.1M
$-133.8M
Q3 25
$61.7M
$79.0M
Q2 25
$58.2M
Q1 25
$56.7M
Q4 24
$36.3M
$-104.7M
Q3 24
$41.3M
$-67.8M
Q2 24
$34.0M
FCF Margin
FRSH
FRSH
MDGL
MDGL
Q1 26
Q4 25
27.0%
-41.7%
Q3 25
28.7%
27.5%
Q2 25
28.4%
Q1 25
28.9%
Q4 24
18.7%
-101.3%
Q3 24
22.1%
-109.0%
Q2 24
19.5%
Capex Intensity
FRSH
FRSH
MDGL
MDGL
Q1 26
Q4 25
1.0%
0.1%
Q3 25
0.8%
0.3%
Q2 25
0.2%
0.0%
Q1 25
0.7%
0.0%
Q4 24
2.6%
0.2%
Q3 24
0.6%
1.3%
Q2 24
1.3%
Cash Conversion
FRSH
FRSH
MDGL
MDGL
Q1 26
Q4 25
0.33×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FRSH
FRSH

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons